Outlining the clinical evidence landscape for FXI(a) inhibition:
- stroke and bleeding prevention for patients with AF at risk of stroke
- secondary stroke prevention in acute non-cardioembolic ischemic stroke or high-risk TIA
Speaker:
Professor J. De Groot (Amsterdam, NL)
Professor M. Sharma (Hamilton, CA)